Filter Results
Clinical Studies
Results filtered:Study status:
Closed for Enrollment
Closed for Enrollment
-
A Phase 1b/2, Open-label Dose Escalation With Expansion Study Of GB5121 In Adult Subjects With Relapsed/Refractory Primary Or Secondary Central Nervous System Lymphoma, With A Phase 2 Open-label Single Dose Level Study Of GB5121 In Adult Subjects With Relapsed/Refractory Primary Central Nervous System Lymphoma
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, is to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.
.